Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 04:00:04 2024-07-12 pm EDT 5-day change 1st Jan Change
40.44 USD -0.76% Intraday chart for Bristol-Myers Squibb Company +1.97% -21.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43 MT
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors CI
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says MT
Eisai Co., Ltd. Agrees to End Its Global Strategic Collaboration with Bristol Myers Squibb for the Co-Development and Co-Commercialization of farletuzumab ecteribulin CI
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Bristol Myers: accelerated approval in colorectal cancer CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval MT
US FDA approves Bristol Myers' colorectal cancer therapy RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo MT
Bristol Myers: application validated for subcutaneous Opdivo CF
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo CI
PTC Therapeutics, Inc. and Hopewell Campus Owner, LLC, as Successor-In-Interest to Bristol-Myers Squibb Company Enter into an Amendment and Restatement of the Lease of Office, Production and Laboratory Space At A Facility Located in Hopewell Township, New Jersey CI
Bristol Myers: ex-CEO of Agilent joins Board of Directors CF
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024 CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment MT
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5 MT
Bristol Myers: Board declares dividend CF
Chart Bristol-Myers Squibb Company
More charts
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.46 USD
Average target price
52.74 USD
Spread / Average Target
+30.35%
Consensus
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company
  5. Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients